Yüklüyor......
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
Pembrolizumab is a monoclonal antibody directed towards programmed cell death protein 1 (PD-1) and is an antineoplastic drug which has a growing variety of oncologic uses. Pembrolizumab is commonly associated with immune-related adverse events (IRAEs) but is infrequently noted to cause cardiotoxicit...
Kaydedildi:
| Yayımlandı: | Case Rep Cardiol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Hindawi
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007942/ https://ncbi.nlm.nih.gov/pubmed/32047674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8428210 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|